Epic Sciences Talks Differentiation And Benefits Of Its DefineMBC Cancer Test

Epic Sciences spoke to Medtech Insight to discuss the development of its DefineMBC test for metastatic breast cancer.

• Source: Shutterstock

Epic Sciences’s DefineMBC laboratory developed liquid biopsy test has been designed to aid clinicians in the identification and classification of metastatic breast cancer.

In May, Epic Sciences released additional data demonstrating its efficacy and on 1 June, the company announced that it...

Welcome to Medtech Insight

Create an account to read this article

More from In Vitro Diagnostics

Waters’ Purchase Of BD Biosciences & Dx Brings Growth Potential Alongside Trade-Offs

 
• By 

Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.

Thena Capital’s New Fund Up And Running With £1M Investment In Plexāā’s Breast Cancer Device

 

Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.

Milner Pitch Day: Multiomic Pathology, Microcancer Avatars And Cell Morphology Intelligence

 

The Milner Institute, the on-campus hub for start-up acceleration at Cambridge University, hosted its annual Pitch Day on July 1. Start-ups Panakeia, PathwayBio and Sentinal4D presented diagnostic technologies.

Dxcover Launches US Operations With New Headquarters In Tennessee

 

Dxcover sets up new Clinical Laboratory Improvement Amendments (CLIA) lab in Franklin, Tennessee.

More from Diagnostics